Caldeira, D.
Alves, M.
Ferreira, J. J.
Pinto, F. J.
Funding for this research was provided by:
Universidade de Lisboa
Article History
Received: 5 October 2022
Accepted: 29 December 2022
First Online: 18 January 2023
Declarations
:
: DC has participated in educational meetings and/or attended a conferences or symposia (including travel, accommodation and/or hospitality) with Bial, Bristol-Myers Squibb, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Merck Serono, Ferrer, Pfizer, Novartis and Roche. JJF is a consultant for Ipsen, GlaxoSmithKline, Novartis, Teva, Lundbeck, Solvay, Abbott, BIAL, Merck Serono, and Merz and received grants from GlaxoSmithKline, Grunenthal, Teva, and Fundação MSD. FJP had consultant and speaker fees with Astra Zeneca, Bayer, BMS, Boehringer Ingelheim and Daiichi Sankyo. The remaining authors have nothing to declare.
: This was a retrospective evaluation of the VITAL trial using data provided by the Project Data Sphere (ExternalRef removed). Detailed methodology and main results of the trial have been published elsewhere. The dataset used is de-identified and public according to request to PDS. This project complies with the principles of the Declaration of Helsinki as revised in 2008.